|
Saturday, March 15, 2025, Seattle, Washington, 12:30 PM – 2:00 PM Pacific Time (3:30 PM – 5:00 PM Eastern Time)
Cases from the Community: Investigators Discuss the Optimal Clinical Care of Patients with HER2-Positive Gynecologic CancersAn Independent CME Symposium During the 2025 SGO Annual Meeting on Women’s Cancer®
Location
Seattle Convention Center 705 Pike Street Seattle, Washington Phone: (206) 694-5000 Program Schedule — Pacific Time 12:00 PM – 12:30 PM — Registration and Lunch Buffet 12:30 PM – 2:00 PM — Educational Meeting Meeting Room Room 6AB – Level 6 Faculty
Kathleen N Moore, MD, MS Deputy Director Virginia Kerley Cade Chair in Developmental Therapeutics Co-Director, Cancer Therapeutics Program Stephenson Cancer Center at the University of Oklahoma HSC Associate Director, GOG Partners Board of Directors, GOG Foundation Board of Directors, ASCO Oklahoma City, Oklahoma Alessandro D Santin, MD Professor Department of Obstetrics and Gynecology Co-Chief, Gynecologic Oncology Yale University School of Medicine New Haven, Connecticut
Moderator
David M O’Malley, MD Director and Professor Division of Gynecologic Oncology in Obstetrics and Gynecology John G Boutselis Chair in Gynecologic Oncology The Ohio State University and The James Comprehensive Cancer Center Columbus, Ohio This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Program Schedule — Pacific Time
12:00 PM – 12:30 PM — Registration and Lunch Buffet 12:30 PM – 2:00 PM — Educational Meeting Module 1: Strategies to Identify Patients with HER2-Positive Gynecologic Cancers
Module 2: Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers
Module 3: Identification and Management of Adverse Events (AEs) with T-DXd
Target Audience
CME Credit Form FACULTY — Dr Santin has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Moore — Advisory Committees: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Blueprint Medicines, Caris Life Sciences, Corcept Therapeutics, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Allarity Therapeutics, Daiichi Sankyo Inc, GSK, ImmunoGen Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics. MODERATOR — Dr O'Malley — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc, GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. Seattle Convention Center
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
There is no registration fee for this event. For the in-person symposium in Seattle, preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the 2025 SGO Annual Meeting on Women’s Cancer®. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. |